It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

1 Predictors of Response to Cardiac Resynchronization Therapy in

# 2 Pediatric and Congenital Heart Disease Patients

3

## 4 Authors

- 5 Henry Chubb MA MBBS PhD<sup>1,2</sup>, Douglas Mah MD<sup>3</sup>, Maully Shah MD<sup>4</sup>, Kimberly Y Lin MD<sup>4</sup>, David
- 6 Peng MD<sup>5</sup>, Benjamin W Hale MD<sup>5,6</sup>, Lindsay May MD<sup>7</sup>, Susan Etheridge MD<sup>7</sup>, William Goodyer<sup>1</sup>,
- 7 Scott R Ceresnak MD<sup>1</sup>, Kara S Motonaga MD<sup>1</sup>, David N Rosenthal MD<sup>1</sup>, Christopher S Almond
- MD MPH $^1$ , Doff B McElhinney MD $^{1,2}$ , Anne M Dubin MD $^1$ 8
- 9

## 10 Author Affiliations

- 11 <sup>1</sup>Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, CA, USA
- 12 <sup>2</sup> Division of Pediatric Cardiothoracic Surgery, Department of Cardiothoracic Surgery, Stanford
- 13 University, CA, USA
- 14 <sup>3</sup> Department of Cardiology, Boston Children's Hospital; Department of Pediatrics, Harvard
- 15 Medical School; Boston MA, USA
- 16 <sup>4</sup> Department of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- 17 <sup>5</sup> Department of Cardiology, CS Mott Children's Hospital, University of Michigan, Ann Arbor,
- 18 MI, USA
- 19 <sup>6</sup> Department of Pediatrics, Stead Family Children's Hospital, Iowa City, IA
- 20 <sup>7</sup> Department of Cardiology, Primary Children's Hospital, University of Utah, Salt Lake City, UT,
- 21 USA
- 22

## 23 Corresponding Author

- 24 Henry Chubb, Clinical Associate Professor, Division of Pediatric Cardiology, Stanford University
- 25 School of Medicine, 750 Welch Road, Stanford, CA 94304
- 26 mhchubb@stanford.edu
- 27
- 28 Total Word Count

It is made available under a CC-BY-NC-ND 4.0 International license.

- 4873 (including manuscript body, references and figure legends)
- 
- Disclosure Statements
- The authors would like to declare the following relationships with industry
- 
- Henry Chubb None
- Douglas Mah None
- Maully Shah- Medtronic Inc- consultant
- Kimberly Lin- None
- David Peng- None
- Benjamin Hale- None
- Lindsay May- None
- Susan Etheridge- None
- William Goodyer- None
- Scott Ceresnak- None
- Kara Motonaga- None
- David Rosenthal- None
- Christopher Almond- None
- Doff McElhinney- Medtronic Inc- Proctor and Consultant
- Anne Dubin- None
- 
- Funding
- None
- 
- Keywords
- Cardiac resynchronization therapy; Congenital heart disease; Cardiac Failure; Pediatric;
- Predictors of Response; Dyssynchrony

## Abstract

## **Background**:

- Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric
- and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection
- fraction (EF). However, the identification of optimal responders is challenging.
- 

## **Objective**:

- To identify predictors of response to CRT in children and CHD patients at 5 large quaternary
- referral centers.
- 

## **Methods**:

- Patients were <21 years or had CHD; had SVEF <45%; symptomatic heart failure; and significant
- electrical dyssynchrony prior to CRT. Primary outcome was defined as an ordinal response at
- 6/12months: (1) Improved EF [≥5%], (2) Unchanged SVEF, (3) Worse SVEF. Secondary outcome
- utilized a propensity score-matched control cohort. Response to CRT was defined using
- longitudinal trajectory of SVEF up to latest follow-up.
- 

## **Results**:

- In total, 167 eligible CRT recipients were identified across the 5 centers. 150 had
- comprehensive data at 6/12months: 96(64%) with improved SVEF, 26(17%) unchanged,
- 28(19%) worsened. Mean increase in SVEF was 11% [IQR 3-21%]. On univariable ordinal
- 77 regression, lower SVEF (p=0.013), biventricular circulation (p=0.022), systemic LV (p=0.021), and
- conduction delay to lateral wall of SV (p=0.01) were associated with positive response.
- 
- 80 For assessment of secondary outcome, 324 controls were identified. Mean follow-up 4.2( $\pm$ 3.7)
- yrs. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with
- systemic RV (p=0.69) or without prior single site pacemaker (p=0.20).
- 

## **Conclusion**:

- CRT in children and CHD patients frequently results in an improvement in SVEF. Those with
- lower SVEF, conduction delay to lateral wall of the SV and those with systemic LV are most
- likely to respond.
- 
- 

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

## Condensed Abstract

- Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric
- and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection
- fraction (EF). However, the identification of optimal responders is challenging.
- 
- In this multicenter study, pediatric and CHD CRT recipients with heart failure and EF<45% were
- identified. The primary outcome was change in EF at 6/12months. Those with lower baseline
- SVEF, conduction delay to lateral wall of the SV and/or systemic LV were most likely to respond
- to CRT. When compared to propensity score-matched controls, the CRT groups also
- demonstrated a significantly better long-term EF trajectory.
- 
- 

## 102 Key Words

- Cardiac Resynchronization Therapy
- Pediatric
- Heart Failure
- Congenital Heart Disease
- Cardiac Transplant
- Electrical Dyssynchrony
- 
- 110 Abbreviations List
- CHD: Congenital Heart Disease
- CRT: Cardiac Resynchronization Therapy
- DCM: Dilated Cardiomyopathy
- EF: Ejection Fraction
- HF: Heart Failure
- HR: Hazard Ratio
- ICD: Implantable Cardioverter Defibrillator
- LV: Left Ventricle
- NYHA: New York Heart Association
- PSM: Propensity Score-Match
- QRSd: QRS Duration
- RV: Right Ventricle
- SV: Systemic Ventricle
- 

It is made available under a CC-BY-NC-ND 4.0 International license.

### Introduction

 Cardiac resynchronization therapy (CRT) is a treatment modality widely employed for patients with significant systemic ventricular (SV) dysfunction and evidence of electrical dyssynchrony. However, evidence for the use of this important treatment is relatively limited in children and congenital heart disease (CHD) patients as all prospective randomized trials of CRT have 130 specifically excluded these subjects.<sup>1-6</sup> None the less, retrospective studies and meta-analysis have clearly demonstrated that many children and CHD patients may benefit from CRT in terms 132 of improvement in systemic ventricular function.<sup>7-11</sup> Furthermore, we have recently demonstrated in a multicenter study that there is a strong association of CRT with survival in a broad group of patients with systemic ventricular ejection fraction (SVEF)<45%, significant 135 electrical dyssynchrony and cardiac failure symptoms.<sup>12</sup> However, the factors that identify those children and CHD subjects that are most likely to respond to CRT have not been defined. The need to identify the pediatric and CHD groups that are most likely to respond to CRT is particularly pertinent in the context of the increased technical challenges of CRT implant procedures compared to adults with structurally normal hearts. The implants may be highly complex and frequently require repeat sternotomy. In adults without CHD, the presence of left

bundle branch block (LBBB), female sex, and longer QRS duration (QRSd) have been identified

143 to be the most robust predictors of response.<sup>13</sup> In the pediatric/CHD patients, though,

144 QRSd>150msec and LBBB are rarely seen.<sup>14</sup>

 In a population as heterogenous as that of children and CHD subjects with systemic ventricular systolic failure, there are many fundamental pathophysiological differences between patients 148 that are likely to play a role in response to CRT. However, the largest retrospective studies of these patients have not concurred as to whether there are distinct subgroups that are more or less likely to respond. Key subgroups for assessment include those with and without prior ventricular pacing, those with and without CHD and then, within CHD, those with and without a 152 biventricular circulation and systemic LV. $^{11, 15}$ 

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

We hypothesized that the assessment within a larger multicenter CRT cohort would be

sufficiently powered to identify key predictors of response to CRT within these patient groups.

Given the challenge in defining response in these heterogenous morphologies, we chose to use

two main outcomes. The first was medium term (6-12month) change in SVEF, referenced to the

patient baseline prior to CRT. The second utilized a matched control group (without CRT) to

- compare the longitudinal impact of CRT.
- 

## Methods

162 Data collection

 This was a multicenter retrospective study. Patient data were de-identified and electronically transferred to the coordinating center through a secure web- based server (REDCap [Research Electronic Data Capture], Vanderbilt University, Nashville, TN). The study was approved by institutional review board (IRB) at the co-ordinating center (Stanford University, IRB-45389), with local IRB and data use agreement approval obtained at each center. The survival outcomes 168 of this cohort have recently been reported. $^{12}$ 

### 170 Study population

 All pediatric (<21years) and/or CHD patients who underwent CRT at five large quaternary referral institutions (Lucile Packard Children's Hospital and Stanford Healthcare, Boston Children's Hospital, Children's Hospital of Philadelphia, Primary Children's Hospital (University of Utah), and CS Mott Children's Hospital (University of Michigan)) between Jan 1, 2004 and Jan 1, 2018 were identified. CRT was defined as a multi-site ventricular pacing system implanted with at least one pacing lead to the systemic ventricle (SV). CHD was defined as any congenital heart defect other than isolated bicuspid aortic valve, patent foramen ovale or patent ductus arteriosus. Subjects were included if, at the time of CRT implant, they had systemic SVEF <45%; symptomatic heart failure [defined as American Heart Association Stage C or D]; and significant electrical dyssynchrony [defined as either a QRSd z-score≥3 or, in paced patients, a ventricular pacing burden (Vp) ≥40%] (Figure 1). Subjects were excluded if they had Eisenmenger syndrome, a current ventricular assist device, previous heart transplant or weight <4kg.

It is made available under a CC-BY-NC-ND 4.0 International license.

 Control subjects were defined as pediatric and/or CHD patients who never received CRT and who met the same inclusion and exclusion criteria at an outpatient clinical encounter within the same time period. Controls were also excluded if there was a documented, planned, intervention for heart failure, such as alleviation of systemic outflow tract obstruction or ablation procedure for high ventricular ectopy burden. However, controls became eligible for enrollment once the intervention had been performed, and, similarly, once weight was >4kg, provided all inclusion criteria continued to be met.

### 192 Identification of Subjects, Enrollment and Follow-Up

 CRT subjects were identified via the institutional pacing databases. For control subjects, a comprehensive screening cohort with low SVEF and electrical dyssynchrony was identified by cross-referencing the institutional echocardiographic, ECG and pacing databases. All patients with both an estimated SVEF <45% and QRSd z-score ≥3 were selected for individual review for fulfillment of inclusion and exclusion criteria. Ventricular pacing-related dyssynchrony was identified via cross-referencing the echocardiographic database with the temporally matched device interrogation report to identify Vp >40% and SVEF <45%. Enrollment for CRT subjects was on the day of CRT implantation. Enrollment for control subjects was at the first outpatient appointment where all inclusion criteria were met.

 Longitudinal assessments of all patients were collected at follow-up closest to 6 months, 1 year, and 5 years post enrollment, and latest follow-up. Precise date of assessment, number of heart failure medications, NYHA class, SVEF, QRSd, height and weight were obtained at each timepoint.

*Electrical Assessment*

209 GRSd was measured in leads II and  $V_5$  and averaged. Strict left bundle branch block (LBBB) was

defined using adaptation of the criteria outlaid by Strauss et al, and was assessed on the surface

211 ECG without reference to underlying cardiac anatomy.<sup>16</sup> Right bundle branch block (RBBB) was

It is made available under a CC-BY-NC-ND 4.0 International license.

- defined according to the Minnesota Code criteria (7-2-1). QRSd z-score equivalent to ≥120ms
- 213 (z-score ≥+2.3) was used along with the published RBBB criteria.<sup>17</sup>
- 

Conduction delay to the lateral wall of the SV (CDtoLWSV) was defined as those patients with

- strict criteria LBBB and SV (which could be morphological left or right ventricle) in the
- conventional left ventricular (LV) position, *or* a RBBB and SV in conventional right ventricular
- (RV) position. Those with complex ventricular arrangement (such as dextrocardia) therefore
- could not be defined as CDtoLWSV, regardless of the ECG morphology.
- 

## *Radiographic Assessment*

Separation of the ventricular pacing leads was assessed on the first biplane chest x-ray

- following CRT implant (Figure 1). Unipolar pacing was rarely employed, and for those with
- multiple poles (eg epicardial bipolar leads), the mid-point of all poles was taken for each

ventricular lead. Total distance in 3-dimensions, assuming orthogonal alignment of the two

- imaging planes, was indexed to the thoracic cavity width, creating a Lead Separation Ratio
- (LSR).
- 

### *Echocardiographic Assessment*

Baseline echocardiographic measurements were made on the final comprehensive

- echocardiogram prior to CRT implant. SVEF for the systemic RV was calculated from the
- 232 fractional area change (RVFAC), using the estimation RVEF =  $10.7 + (0.87 * RVFAC).$ <sup>18</sup>
- 

## 234 First Definition of Response: Medium-Term Change in SVEF from Baseline

There is no clear consensus on the optimal marker of response to CRT, particularly in the CHD

- 236 population where many patients have differing systemic ventricular morphology. Most non-
- 237 CHD studies of CRT response have used a  $\geq$ 15% reduction in LVESV as a threshold, but such a
- 238 measure is not universally applicable in patients with mixed ventricular anatomy.  $^{13, 19}$  Studies
- 239 of CRT including CHD subjects have historically used a variety of measures of change in SV

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 240 ejection fraction EF.<sup>7-9, 11</sup> A primary outcome of an echocardiographic functional response was
- therefore defined as follows:
- 242 1. Worsened: fall in SVEF at follow-up following CRT implant
- 2. No change: absolute increase in SVEF of between 0% and 5%
- 3. Improvement: absolute increase in SVEF of ≥5%
- 
- Other studies have used a proportional increase in SVEF as a marker of response, with the
- rationale that larger (but sometimes less clinically significant) changes may occur in patients
- with higher baseline EF, potentially biasing results. Therefore, a proportional response was also
- defined in order to further enable comparison between studies:
- 1. Worsened: fall in SVEF at follow-up following CRT implant
- 2. No change: proportional increase in SVEF of between 0% and 10%
- 3. Improvement: proportional increase in SVEF of ≥10%
- 

Echocardiographic parameters were assessed at closest follow-up to 6 months post implant and

- 12 months post implant for all patients. Follow-up at both time points was available in many,
- but not all, patients. Following sensitivity analyses for those with assessments recorded at both
- 6 and 12 months (see results), the average of the two measurements was used in order to
- mitigate for variations in time to assessment.

- 260 Second Definition of Response: Longitudinal Trends with and without CRT
- The identification of propensity score matched controls has been described in detail in a prior
- 262 publication from our group, and the tables detailing the baseline parameters of the
- unmatched and matched cohorts meeting inclusion criteria for each analysis are included in the
- Data Supplement. Response to CRT was defined as a significant positive impact of CRT upon
- longitudinal modelling of the long-term parameters (see statistical details below).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### 267 Statistics

 Mean ± standard deviation was used to summarize normally distributed continuous variables, 269 and median (with 25<sup>th</sup>-75<sup>th</sup> percentiles) was used for non-normal distribution or non-continuous ordinal data. Categorical variables are presented as number (%). A priori, six anatomical and 271 pathophysiological subgroups were established by firstly dividing the cohort into those with and without prior significant ventricular pacing (defined as Vp>40% prior to CRT), and then further subdividing into three anatomical subgroups: those without CHD, those with CHD with two ventricles and systemic LV, and those with other ('complex') CHD. Between-group variation was quantified using one-way ANOVA for normally distributed variables and Kruskall-Wallis for non- normal/categorical variables. Ordinal logistic regression was used to assess the association of indices with ordinal outcomes (worse/no change/improved absolute or proportional change in SVEF). Multivariable modelling used a stepwise approach taking forward parameters with p<0.05 on univariable analysis. Multivariable modelling was performed without inclusion of the subgroup 1-6 variable on

account of collinearity, except on direct assessment of the significant subgroups. Longitudinal

measures were evaluated using multilevel mixed-effects linear regression modeling with cubic

model for estimation of pacing effect and visualized using fractional polynomial plot with 95%

CIs. Statistics were analyzed using Stata (version 18.0, Stata Corp LP, College Station, Texas).

It is made available under a CC-BY-NC-ND 4.0 International license.

#### Results

288 Subjects

Baseline characteristics are delineated in Table 1. A total of 167 eligible CRT subjects were

- identified, of whom 105 (63%) were V-paced>40% at final follow-up prior to commencement of
- CRT. 122 (73%) had congenital heart disease, the majority of whom (85 (70%)) had a
- biventricular circulation with systemic LV. A structural surgical procedure was performed within
- 30days before or after the implant of the CRT system in 34 (20%) subjects, 29 (85%) of which
- were at the same procedure.
- 
- Between the 6 pre-defined subgroups, several trends in baseline indices were noted. Those
- with prior pacing (Groups 1, 2 and 3) had a very high median pacing percentage (100% [100-
- 100%]). Compared to the non-paced cohorts (Groups 4,5 and 6) they were similar in age at
- enrollment (9.8 [3.8-20] years versus 14.9 [9.2-20] years, p=0.13) and had similar SVEF
- 300 (30.8 $\pm$ 8.9% versus 31.8 $\pm$ 8.5%, p=0.49), but tended to have wider QRSd at baseline (165 $\pm$ 26ms
- 301 versus 149±28ms, p=0.0003).
- 
- CRT delivery was good throughout follow-up with median pacing percentage 100% [100-100%] at all follow-up time points. Follow-up was recorded close to the target dates of 6months post implant (actual timing 5.8months [4.1-6.7months] post implant), 12 months (12.4months [11.1- 13.9months]), 5 years (5.0 [4.7-5.4years]) and latest follow-up (5.1 years [2.0-8.6 years]).
- 
- 

### Response Definition 1: Improvement in SVEF within the First Year Post-CRT

#### *Response to CRT*

- Formal assessment of SVEF was available for 150 (90%) subjects for at least one of the
- stipulated 6 month or 12 month time points. 90 (60%) had follow-up available at both time
- points, with excellent intraclass correlations between the SVEF measurements made at the two

It is made available under a CC-BY-NC-ND 4.0 International license.

- time points (average ICCs, two-way mixed effects, absolute agreement: SVEF 0.91 (95% CI 0.86-
- 0.94)). Average values were taken for those with two follow-up measurements.
- 
- Across all subjects with formal SVEF measurements, 96 (64%) exhibited an improvement in
- absolute SVEF >5% and 110 (73%) a proportional improvement in SVEF >10% (Table 2 and
- Figure 2). Overall, there was an median increase in SVEF of 11% [3-21%] (p<0.001 compared to
- 321 baseline), and a decrease in QRS duration ( $18\pm 24$ msec, p<0.001), QRSd z-score ( $1.9\pm 2.4$ ,
- 322 p<0.001) and NYHA class (0.6 $\pm$ 1 lower, p<0.001), but no change in number of HF medications
- 323  $(0.04\pm0.92, p=0.63)$ . Between subgroups, there was minimal variation in degree of change of
- clinical parameters, except for QRSd and QRSd z-score, which shortened more in the prior
- 325 paced groups (delta of 22 $\pm$ 21ms versus 8 $\pm$ 25ms, p<0.001 and delta of 2.5 $\pm$ 2.1 versus 1.0 $\pm$ 2.5,
- p<0.001, respectively).
- 

328 There was minimal correlation between change in EF and change in QRSd (p=0.10,  $R^2$ =0.01) or

- 329 QRSd z-score (p=0.044,  $R^2$ = 0.03), suggesting that the crude shortening of QRSd was not highly
- significant in determining EF improvement following CRT. Improvement in EF was more strongly
- 331 correlated with improvement in NYHA class (p<0.001,  $R^2$ =0.12).
- 
- 
- *Morphological and pathophysiological predictors of response*
- Factors associated with the response to CRT by ordinal logistic regression are shown in Table 3.
- The pathophysiological groups 1-5 were not significantly associated with response, and only
- Group 6 (no prior pacing, complex CHD) differed significantly from the other groups. This group
- was least likely to demonstrate a response to CRT in terms of either an absolute (coefficient -
- 2.2 [ -3.6 -0.8), p=0.002) or proportional response (coefficient -1.4 [ -2.9 -0.03), p=0.046).
- 
- Other predictors of response differed between the absolute and proportional SVEF
- improvement assessments. On analysis of predictors of absolute SVEF improvement (>5% rise
- in SVEF), patients with lower baseline SVEF were more likely to experience a beneficial

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- response, on both univariable and multivariable analysis. Those with biventricular circulation,
- systemic LV, CDtoLWSV and lower lead separation ratio were more likely to respond on
- univariable but not multivariable analysis.
- 
- On assessment of predictors of proportional improvement in SVEF, a lower SVEF was again a
- significant predictor on univariable and multivariable response, as was CDtoLWSV.
- 
- The association of SVEF and response (absolute and proportional) is demonstrated in Figure 3.
- The coefficient for response was significantly worse for those with higher SVEF. All higher SVEF
- groups were associated with significantly lower response coefficient (p<0.05) on absolute
- 354 response, with the exception of the 3<sup>rd</sup> tertile (36/45%) and 4<sup>th</sup> quintile (36/40%). All higher
- SVEF groups were associated with significantly lower response coefficient on proportional
- 356 response, with the exception of the  $2^{nd}$  quartile (25/31%).
- 
- 
- Response Definition 2: Longitudinal Improvement in Parameters versus Control Groups
- *Response to CRT*
- Across the whole cohort (139 propensity matched pairs, total 278 subjects), there was a clear longitudinal impact of CRT upon SVEF (CRT coefficient 4.0 (1.9-6.1), p<0.001) and QRS duration z-score (-0.7 (-1.2- -0.2), p=0.015). There was no significant CRT-associated longitudinal impact upon NYHA class, total number of HF medications, or somatic growth (in terms of weight or height). There remained no association of CRT with somatic growth on subanalysis of subjects prior to age 18years (192 PSM subjects, Height: 493 measurements, CRT coefficient 1.02 (-8.7- 11), p=0.84); Weight: 507 measurements, CRT coefficient 0.95 (-6.4-8.3), p=0.80).
- 
- *Morphological and pathophysiological predictors of response*
- Longitudinal change in SVEF was assessed within the primary binary subgroups [with/without
- pacing, with/without CHD, with/without biventricular circulation, with systemic LV or RV]. A
- significant positive association of SVEF with CRT was seen in 6 of the 8 subgroups (75%) (Figure

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 4). The relationship between CRT and longitudinal SVEF was not significant in patients with a
- systemic RV, those who were not paced prior to enrollment, and in subgroups with small
- numbers.
- 

#### Sensitivity analyses

- Excluding subjects who underwent concurrent surgical procedures within 30days either side of
- CRT implant (n=34), overall change in SVEF was similar at +10% [3-21%] across all 118 subjects
- with early formal SVEF assessment. 74 (63%) were responders in terms of absolute
- improvement in SVEF and 87 (74%) were responders in terms of proportional improvement in
- SVEF. Significant univariable and multivariable predictors of response remained unchanged,
- except that CDtoLWSV was now a significant predictor of absolute response on multivariable
- analysis (0.93 [0.06-1.83], p=0.032) as well as univariable. On longitudinal analysis of PSM
- subjects and controls (252 PSM subjects, 830 measurements), SVEF remained significantly
- associated with CRT (CRT coefficient 2.7 (0.2-5.2), p=0.038).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



It is made available under a CC-BY-NC-ND 4.0 International license.

#### 415 Patient Anatomical and Pathological Variants

 By the nature of the patient cohort, there was considerable heterogeneity between each subject. Each subject presents a unique constellation of patient-specific factors, all of which may impact upon CRT response. There is a constant pull between the desire to define the patient groups as homogenously as possible versus the obligation to avoid creating ever smaller divisions that preclude the possibility of meaningful comparison. The six groups were designed to map onto those patient groups that have been defined in prior studies to be potentially good  $\phantom{1}$  or poor responders to CRT.<sup>11</sup> These include pacing-induced cardiomyopathies, systemic LVs, 423 systemic RVs and univentricular circulations  $7-9$ ,  $20$ ,  $21$ .

### Highest Likelihood of Response

 The absence of consistent significant associations between most of the anatomical and pathological groups and subsequent response to CRT is a significant finding. On assessment of early response (using the patient as their own baseline), the most consistent finding was that 429 patients with lower SVEF tended to be most likely to demonstrate not only a proportional response, but also an absolute response (>5% improvement). This suggests that there may not be a clear cutoff to define when CRT is 'too late', and that even those with severely impaired function may experience an increase in SVEF with CRT.

 Conduction delay to the lateral wall of the systemic ventricle was also a parameter that was significant on univariable analysis of absolute response, and both univariable and multivariable analysis of proportional response. This measure was selected as analogous to LBBB in the functionally normal heart, and may be an important indicator in more complex hearts. Further research is required to assess whether this is associated with epiphenomena such as classical 439 pattern dyssynchrony in the CHD population.<sup>22</sup> However, the fact that it was rarely seen in the complex CHD groups (16% of subjects), and yet the response rate in those groups was 40-60%, suggests that this relatively crude index of electrical activation is a useful but not an essential criterion for response to CRT.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 In contrast to many non-CHD adult CRT studies, it was notable that increased QRSd alone was not associated with response by any measure. Some of this difference may be accounted for by the heterogeneity of interventricular conduction delays, but the most significant fact is likely that the vast majority of recipients had a 'sufficient' degree of electrical dyssynchrony. 156 (93%) had a QRSd z-score>3.55 (the cutoff employed as a marker of equivalency for strict LBBB criteria), and 145 (87%) had QRSd z-score >4.8, the equivalent to around 150msec and the longest QRSd cutoff evaluated in major conventional CRT trials.

#### Lower Likelihood of Response

 On longitudinal assessment versus controls, patients without prior ventricular pacing and those with systemic RV did not demonstrate a superior outcome with CRT (Figure 4). This trend was also reflected in the lower medium-term response rates in the group with no prior pacing, and CHD without a biventricular, systemic LV, circulation. Again, in such a heterogenous group, identifying the underlying reasons for these findings is challenging, but a number of factors may be postulated.

## *CRT in Patients without Biventricular Circulation*

 Increasingly, large studies have demonstrated that ventricular pacing of the single ventricle patient is highly deleterious to long term survival, but no study has identified a clear 463 improvement in outcome with CRT.<sup>23, 24</sup> At least in part, this is likely related to the limited number of single ventricle patients receiving CRT systems. Numbers in this study remain relatively small, but nevertheless, we identified a significant impact of CRT on long-term SVEF trends. The second response outcome of the study, longitudinal trends versus matched controls, assists determining whether differing responses to CRT are related to weaker effect of CRT or the higher overall risk of deterioration in specific patient groups. In this context, there is an argument that, for patients with a single ventricle, the absence of deterioration may itself be a good response to CRT, and this would explain the discrepancy between the univariable findings of medium-term response (where there is a trend to better CRT response in

It is made available under a CC-BY-NC-ND 4.0 International license.

- biventricular patients) and the longitudinal response versus controls. A similar trend in the
- 473 single ventricle population has been demonstrated previously by the Boston group.<sup>25</sup>
- 

### *CRT in Patients with Systemic Right Ventricle*

 The other major anatomical subgroup that has received individual attention in most prior 477 studies is patients with systemic RV. Published results in this cohort have been mixed at best. 478 While some studies have found an attenuated response to CRT  $8, 9, 26$ , others showed no 479 Fesponse.<sup>7, 21</sup> A recent metanalysis found a marginally inferior response in the systemic RV 480 population.<sup>11</sup> Our study again found a mixed picture. On medium-term SVEF response, there was a weak (univariable only) trend towards poorer response to CRT, while on longitudinal outcome versus controls there was no significant CRT effect. These findings may be partially attributed to challenges in measuring the EF of the systemic RV, and the latter finding may relate predominantly to sample size (Figure 4). As such, these findings certainly do not suggest that CRT is contraindicated in the systemic RV population, but there is at least weaker evidence of efficacy.

### 488 Clinical Implications

 This study has demonstrated that CRT results in a clear improvement in SVEF in many pediatric and CHD patients, with responders identified in all anatomical and pathophysiological subtypes. 

 However, CRT remains a complex intervention with significant risks anticipated both at the time of implant (particularly in those requiring repeat sternotomy) and in a life-time of device management. Therefore, indices to identify those who are most likely to respond remain helpful in weighing risk and benefit. On assessment of both medium-term change in SVEF and longitudinal trajectory versus controls there are significant trends that should be noted. Based upon this data, those with lower SVEF, those with electrical conduction delay to the lateral wall of the systemic ventricle (such as LBBB in those with conventional ventricular orientation) and those with systemic LV are most likely to experience a medium and long-term response.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### Limitations

 This was a multicenter retrospective study, and as such the delineation of a clinical response to CRT is highly challenging. We have attempted to be as comprehensive as possible, using two outcome measures, one indexed to the patient and one to a tightly matched control group. It is also established that SVEF alone is not the only marker of response, and prospective studies would be significantly enhanced by the formal evaluation of baseline parameters such as cardiopulmonary metabolics and laboratory studies such as BNP or NT-proBNP.

We chose to include patients with concurrent surgery in the main analyses. Many of these

surgical procedures were on the subpulmonary ventricle, but nonetheless, there are inevitably

hemodynamic implications for the systemic ventricle and general clinical condition resulting

from all structural surgical interventions. Sensitivity analyses suggested a similar result for the

main clinical analyses.

 In a similar vein, in common with all major studies of CRT in these patient cohorts, the pediatric and CHD groups have been amalgamated for many of the analyses. HF in pediatric patients without CHD represents a very different pathology to HF in those with CHD, and there is an argument that they should be assessed entirely separately. However, the numbers of patients in each subgroup were small and we have generally aimed for a robust assessment on multivariable analysis to assess and quantify the role of contributing factors.

## Conclusions

 CRT in children and patients with CHD frequently results in an improvement in SVEF. This study suggests that all the major anatomical and pathophysiological subgroups have the potential to respond to CRT. However, those with lower SVEF, those with electrical conduction delay to the lateral wall of the systemic ventricle (such as LBBB in those with conventional ventricular orientation), and those with systemic LV are most likely to experience a medium- and long-term response.

It is made available under a CC-BY-NC-ND 4.0 International license.

## References

 1. Epstein AE, DiMarco JP, Ellenbogen KA, Estes Iii NAM, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC and Hayes DL. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. *Circulation Journal*. 2013;127:e283-352.

 2. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, et al. Cardiac Resynchronization in Chronic Heart Failure. *New England Journal of Medicine*. 2002;346:1845-1853.

 3. Bristow MR, Saxon LA, Boehmer JP, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *New England Journal of Medicine*.

2004;350:2140-50.

 4. Linde C, Abraham WT, Gold MR, St. John Sutton M, Ghio SDaubert C. Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. *Journal of the American College of Cardiology*. 2008;52:1834-1843.

 5. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes Iii NAM, Foster E, Greenberg H, Higgins SL, et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. *New England Journal of Medicine*. 2009;361:1329-38.

 6. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, et al. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. *New England Journal of Medicine*. 2010;363:2385-2395.

 7. Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, Shannon KM, Temple J, Rosenthal E, Zimmerman FJ, et al. Resynchronization Therapy in Pediatric and Congenital Heart Disease Patients. *J Am Coll Cardiol*. 2005;46:2277-2283.

 8. Janoušek J, Gebauer RA, Abdul-Khaliq H, Turner M, Kornyei L, Grollmuß O, Rosenthal E, Villain E, Früh A, Paul T, et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: Differential effects in various anatomical and functional substrates. *Heart*. 2009;95:1165-1171.

 9. Cecchin F, Frangini Pa, Brown DW, Fynn-Thompson F, Alexander ME, Triedman JK, Gauvreau K, Walsh EP and Berul CI. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years experience in a single institution. *Journal of cardiovascular electrophysiology*. 2009;20:58-65.

10. Chubb H, Rosenthal DN, Almond CS, Ceresnak SR, Motonaga KS, Arunamata AA, Long J,

Trela AV, Hanisch D, McElhinney DB and Dubin AM. Impact of Cardiac Resynchronization

 Therapy on Heart Transplant-Free Survival in Pediatric and Congenital Heart Disease Patients. *Circ Arrhythm Electrophysiol*. 2020;13:e007925.

11. Tokavanich N, Mongkonsritragoon W, Sattawatthamrong S, Techasatian W, Siranart N,

Prasitlumkum N, Navaravong L and Chokesuwattanaskul R. Outcomes of cardiac

resynchronization therapy in congenital heart disease: A meta-analysis and systematic review. *J* 

*Cardiovasc Electrophysiol*. 2024;35:249-257.

12. Chubb H, Mah D, Shah M, Lin KY, Peng D, Hale B, May LJ, Etheridge SP, Goodyer W,

 Ceresnak S, et al. Multicenter Study of Survival Benefit of Cardiac Resynchronization Therapy in Pediatric and Congenital Heart Disease. *JACC Electrophysiology*. 2024.

- 13. Rickard J, Michtalik H, Sharma R, Berger Z, Iyoha E, Green AR, Haq N and Robinson KA. Predictors of response to cardiac resynchronization therapy: A systematic review. *Int J Cardiol*. 2016;225:345-352.
- 14. Schiller O, Dham N, Greene EA, Heath DM, Alexander MEBerul CI. Pediatric dilated cardiomyopathy patients do not meet traditional cardiac resynchronization criteria. *Journal of Cardiovascular Electrophysiology*. 2015;26:885-889.
- 15. Chubb HMotonaga KS. Cardiac resynchronization and implantable defibrillators in adults with congenital heart disease. *Heart Fail Rev*. 2020;25:657-670.
- 16. Strauss DG, Selvester RHWagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy. *Am J Cardiol*. 2011;107:927-34.
- 17. Prineas R, Crow RH B. *The Minnesota Code Manual of Electrocardiographic Findings Standards and Procedures for Measurement and Classification*. London: John Wright/PSG Inc; 1982.
- 18. Anavekar NS, Gerson D, Skali H, Kwong RY, Yucel EKSolomon SD. Two-dimensional assessment of right ventricular function: an echocardiographic-MRI correlative study. *Echocardiography*. 2007;24:452-6.
- 19. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, Abraham WT, Ghio S, Leclercq C, Bax JJ, et al. Results of the predictors of response to CRT (PROSPECT) trial.
- *Circulation*. 2008;117:2608-2616.
- 20. Flugge AK, Wasmer K, Orwat S, Abdul-Khaliq H, Helm PC, Bauer U, Baumgartner H, Diller GP and German Competence Network for Congenital Heart Defects I. Cardiac resynchronization therapy in congenital heart disease: Results from the German National Register for Congenital Heart Defects. *Int J Cardiol*. 2018;273:108-111.
- 21. Koyak Z, de Groot JR, Krimly A, Mackay TM, Bouma BJ, Silversides CK, Oechslin EN, Hoke U, van Erven L, Budts W, et al. Cardiac resynchronization therapy in adults with congenital heart disease. *Europace*. 2018;20:315-322.
- 22. Risum N, Jons C, Olsen NT, Fritz-Hansen T, Bruun NE, Hojgaard MV, Valeur N, Kronborg
- MB, Kisslo J and Sogaard P. Simple regional strain pattern analysis to predict response to cardiac resynchronization therapy: Rationale, initial results, and advantages. *American Heart*

*Journal*. 2012;163:697-704.

- 23. Poh CL, Celermajer DS, Grigg LE, Kalman JM, McGuire MA, Gentles TL, Radford DJ,
- Bullock A, Disney PJS, Winlaw D, et al. Pacemakers are associated with a higher risk of late death and transplantation in the Fontan population. *Int J Cardiol*. 2019;282:33-37.
- 24. Bulic A, Zimmerman FJ, Ceresnak SR, Shetty I, Motonaga KS, Freter A, Trela AV, Hanisch
- D, Russo L, Avasarala K and Dubin AM. Ventricular pacing in single ventricles—A bad combination. *Heart Rhythm*. 2017;14:853-857.
- 25. O'Leary ET, Gauvreau K, Alexander ME, Banka P, Bezzerides VJ, Fynn-Thompson F,
- Triedman JK, Walsh EP and Mah DY. Dual-Site Ventricular Pacing in Patients With Fontan
- Physiology and Heart Block: Does it Mitigate the Detrimental Effects of Single-Site Ventricular
- Pacing? *JACC Clin Electrophysiol*. 2018;4:1289-1297.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 26. Sakaguchi H, Miyazaki A, Yamada O, Kagisaki K, Hoashi T, Ichikawa HOhuchi H. Cardiac
- Resynchronization Therapy for Various Systemic Ventricular Morphologies in Patients With
- Congenital Heart Disease. *Circulation Journal*. 2015;79:649-655.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

## 618 Tables



619 *Table 1. Baseline Demographics. BiV: biventricular, SV EF: systemic ventricle ejection fraction,* 

620 *NYHA: New York Heart Association, HTX: heart transplant listing prior to implant, HF: heart* 

621 *failure, PPM: permanent pacemaker, Vp: ventricular pacing, CRT-D: cardiac resynchronization* 

622 *therapy-defibrillator.*

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

## 623



624 *Table 2. Response to CRT by Subgroup. Please see methods for definitions of improvement/no* 

625 *change/worsening of primary Endpoints. p-value is one-way ANOVA, grouped by the six* 

626 *subtypes.* 

627

It is made available under a CC-BY-NC-ND 4.0 International license.



629 Table 3. Association of baseline characteristics and change in systemic ventricular ejection

630 fraction following CRT. Ordinal logistic regression, with categories as defined in methods.

631 \* For the multivariable analysis of Subgroup 6, Systemic LV and biventricular circulation were

632 excluded due to collinearity

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .



*Figure 1. Measurement of separation of the ventricular leads. Top row- endovascular system,* 

*bottom row- epicardial system.* 

It is made available under a CC-BY-NC-ND 4.0 International license.



*Figure 2. Change in systemic ventricular ejection fraction with time from CRT implant (split x-*

- *axis). CHD: congenital heart disease, BiV: biventricular, SysLV: systemic left ventricle. Best fit*
- *line calculated using cubic regression.*

It is made available under a CC-BY-NC-ND 4.0 International license.



*Figure 3. (Upper) Frequency histogram of systemic ventricle ejection fraction (SVEF) at baseline.* 

*(Lower) Coefficient for response (ordinal regression) versus lowest quintile/quartile/tertile for* 

*absolute SVEF response (Abs) and proportional SVEF response (Prop). Upper and lower tertile* 

*cutoffs were 10/28%, 28/35% and 36/45%, respectively. Quartile cutoffs were 10/25%, 25/31%,* 

*31/37% and 37/45%. Quintile cutoffs were 10/24%, 24/30%, 30/35%, 36/40%, and 40/45%.*

It is made available under a CC-BY-NC-ND 4.0 International license.



 *Figure 4. Longitudinal plots presenting the long-term trajectory of systemic ventricle ejection fraction (SVEF) within the eligible propensity score matched (PSM) cohorts with and without CRT. Separate PSM was performed for each subanalysis. Plots are fractional polynomial plots* 

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 650 *and the pacing effect is estimated using multilevel mixed-effects linear regression modeling with*
- 651 *cubic model.*